JSKN016

DRUG3 trials

Sponsors

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Conditions

Advanced Non-small Cell Lung CancerInoperable Locally Advanced HER2-Negative Breast CancerMetastatic HER2-Negative Breast Cancer

Phase 1

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

RecruitingNCT06868732

Jiangsu Alphamab Biopharmaceuticals Co., LtdAdvanced Non-small Cell Lung Cancer

Start: 2025-04-02End: 2028-12-30Target: 288Updated: 2026-03-30

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

RecruitingNCT06942234

Jiangsu Alphamab Biopharmaceuticals Co., LtdInoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer

Start: 2025-06-01End: 2027-12-31Target: 180Updated: 2025-09-17

Phase 2

Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study

Not yet recruitingNCT06775483

Jiangsu Alphamab Biopharmaceuticals Co., LtdAdvanced Non-small Cell Lung Cancer

Start: 2025-01-17End: 2027-11-30Target: 220Updated: 2025-01-15